CNine Biosolutions is a biotechnology company founded in 2013 and based in Birmingham, Alabama. The company's focus is on advancing diagnostic precision through exploring the uncharted potential of the complement system in infectious diseases, with a specialization in the central nervous system. With an emphasis on complement biology, CNine Biosolutions aims to fill the gap in diagnostic management for infectious diseases, particularly those affecting the central nervous system.
Notable investment activity includes a $2.00M Seed Round investment on 20 April 2018, reflecting confidence in the company's innovative approach to diagnostic solutions. Although the specific investors for the last investment round are not disclosed, this funding injection signifies external support for CNine Biosolutions' mission.
Operating in the Biotechnology and Health Care industries, CNine Biosolutions is positioned at the intersection of scientific exploration and medical advancement, offering a compelling opportunity for investors seeking to support pioneering ventures in the life sciences sector.
